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Agenda 
 
Day 1 Monday 9 February 
0900 Opening, welcome, objectives Vish Nene 
 Agenda, process, introductions Peter Ballantyne 
1000 Consortium ‘annual report’ on progress Vish Nene 
1030 Break  
1100 Year 1 review – Objective 2: To induce antibody based immunity by 
targeting the sporozoite stage of the parasite. 
 
Activities: 
1. Re-assessment of the sporozoite p67 molecule as a candidate 
vaccine antigen (thoughts on NIT assays) 
2. Immunization studies with PIM and characterization of sporozoite 
ligands and host cell receptors that mediate the infection process  
3. Antibodies to define novel candidate sporozoite vaccine antigens 
4. Genomic based method to dissect bovine antibody responses 
5. Recombinant antibodies 
6. p67 peptide chips and epitope mapping 
 
 
 
 
Anna Lacasta 
Ine de Goeyse 
Lucilla Steinaa 
Roger Pelle 
Fred Fellouse 
Soren Buus 
1300 Lunch  
1400 SWOT on the science, the development, the management Interactive exercise 
1500 Break  
1530 Year 1 review – Objective 1: To improve aspects of the current live 
infection and treatment method ECF vaccine AND Objective 4: 
Application of evolutionary and comparative pathogen genomics to ECF 
vaccinology 
 
Activities: 
1. Improve the ITM production process 
2. Generation of a genome wide locus specific map of genetic 
variation of T. parva 
3. Use a genomics approach to prioritize genes as candidate vaccine 
antigens 
4. Determining sporozoite counts 
5. Development of a tick challenge model 
 
 
 
 
 
 
Jeremy Salt 
Joana Silva 
Joana Silva 
Ine de Goeyse 
Glen Scoles 
1645 WORKSHOP  
1. ECF index and LD70/LD100 challenge – Lucilla/Tim 
2. p67 way forward and other sporozoite antigens – Anna/Roger 
3. Sporozoite purification, quantification and ITM – Ina 
4. Computational resources – Joana and Morten 
 
4 short starter pointers; then groups to discuss, then plenary synthesis 
 
 
1) take stock what is 
happening in the 
consortium and 2) 
identify specific 
activities or actions for 
the consortium 
 
Day 2 Tuesday, 10 February 
0830 Recap and plans for the day  
0845 Year 1 review – Objective 3: To induce T-cell mediated immunity by 
targeting the schizont stage of the parasite AND NBCRI Feed the 
Future activities 
 
Activities included: 
1. Characterize the magnitude, kinetics and functional profile of the 
protective T cell response AND Evaluate Ad5/MVA antigen 
delivery systems. 
2. Assess the requirements for induction of a protective T cell 
 
 
 
 
 
Tim Connelley 
Ivan Morrison 
Lindsay Fry 
Nick Svitek 
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response AND Identify additional CD8 antigens  
3. Identify additional CD4 antigens and phenotypic data on ECF 
4. Evaluate Ad5/MVA antigen delivery systems  
5. Evaluate a BHV antigen delivery system 
6. Use of heat shock proteins for induction of CTL immunity 
7. CTL-induction: adjuvant and reagents (CAF-9 adjuvant, alphavirus, 
nano-beads) 
8. Yeast expression systems and the RVC activities 
Don Knowles 
Roger Pelle  
Lucilla Steinaa 
Dirk Werling 
1100 Break  
1130 WORKSHOP 
1. Antigen delivery systems / correlation with CTL – Ivan/Lucilla 
2. Reagents, assays, viral vector production, peptide screening – Tim 
Connelly / Nick Svitek 
3. Peptide proteomics and BoLA reagents (Soren Buus) 
4. Peptide proteomics (Nicola Ternette)  
 
1) take stock what is 
happening in the 
consortium and 2) 
identify specific 
activities or actions for 
the consortium 
1300 Lunch  
1400 Results framework – validation and confirmation of expected activities 
and roles 
Grouped by objectives 
1515 Break  
1545 Year 1 Review – synthesis of Objectives 1-4 Plenary interaction 
Grouped by objectives  
 
DAY 3 Wednesday, 11 February 
0830 Recap and plans for the day  
0845 WORKSHOP conversations – inter-lab conversations 
Program management meeting (PMC and EAC members) 
 
1100 Break  
1130 Managing and delivering the program 
 Results Framework 
 Data & reagent sharing, release and publications 
 Budget management and reporting 
 Science reporting 
 On line meetings, minutes, archiving, PR 
 Annual meetings 
Plenary interaction 
1300 Lunch  
1400 The BIG picture - Strategy refresh/revisit – brainstorm  
1500 Break  
1530 Report from management meeting 
Actions, plans, next steps  
Vish Nene 
1645 Plenary reflections  
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Presentations and posters 
All presentations and posters listed are available to project participants in the Yammer network. 
 
Presentations 
0. Introduction to the 2015 Annual ECF Consortium workshop – Vish Nene 
1. Re-assessment of p67C Protein and thoughts in Seroneutralization Assay - Anna Lacasta  
2. Guava research - Ine de Goeyse 
3. Antibodies to define novel candidate sporozoite vaccine antigens - Lucilla Steinaa  
4. Genomic based method to dissect bovine antibody responses - Roger Pelle 
5. Antibody phage display and recombinant antibody methods for antibody and antigen 
discovery and mapping antibody responses to p67C - Frederic Fellouse, Valencio Salema 
and Sachdev Sidhu 
6. High-throughput discovery of B-cell epitopes using high-density peptide microarrays - 
Søren Buus and Morten Nielsen 
7a. Improving the ITM production process - George Chaka 
7b. ITM Process Improvement at CTTBD, Lilongwe - David Kalenzi 
8. Genome re-annotation and identification of putative antigens: 2014 brief review - Joana 
Silva, Kyle Tretina, Joshua Orvis, Tim Gotia, Roger Pelle, Kemi Abolude, Priti Kumari, Shaikh 
Iqbal, Richard Bishop, Claudia Daubenberger  
9. Genome-wide genetic variation: 2014 Brief review - Joana Silva, Elliott Drábek, Daniel 
Harris, Joshua Orvis, Kyle Tretina, Tim Gotia, Richard Bishop, Claudia Daubenberger  
10. PIM immunization studies - Ine De Goeyse  
11. Development of a Tick Challenge Model - Cassandra Olds, Lindsay Fry, Don Knowles and 
Wendy Brown  
12. Characterizing the magnitude, kinetics and functional profile of the protective T-cell 
response and evaluate Ad5/MVA antigen delivery systems - Tim Connelley  
13a. Determining requirements for induction and recall of an effective CD8 T cell response - 
Ivan Morrison 
13b. Identifying new schizont antigens recognised by parasite-specific T cells from immune 
cattle - Ivan Morrison 
14. Selection of T. parva CD4+ T-cell Candidate Antigens and T. parva Immunopathogy - L. Fry, 
D. Knowles, D. Nelson, I. Morrison, T. Connelley, J. Silva, G. Scoles, C. Olds, and W. Brown  
15. Evaluating the Ad5/MVA antigen delivery systems - Nicholas Svitek, Rosemary Saya, Elias 
Awino, Stephen Munyao, Thomas Njoroge, Sarah Gilbert, Vish Nene, Lucilla Steinaa  
16. Bovine Herpesvirus-4 as a delivery platform for Theileria parva antigens - L. Williams, I. 
Morrison, N. Machugh, W. Brown, L. Fry, D. Knowles and G. Donofrio 
17. Use of heat shock proteins for induction of CTL immunity - Charity Muthoni, Benjamin 
Nzau and Roger Pelle 
18. CTL-induction, adjuvants and reagents - Lucilla Steinaa  
19. Yeast expression systems and RVC activities - Shan Goh and Dirk Werling 
20. Identification of MHCI-associated peptides using LC-MS/MS - Nicola Ternette 
21. ECF Project Management Report For the period October 2013–December 2014 - David 
Kiereini 
Posters 
 Role of CD4 T cell responses in immunity against the schizont stage of T. parva – Charlotte 
Bell and Ivan Morrison 
 Irradiated autologous cells induce cytotoxic CD8 T cell responses but delayed protection – 
Charlotte Bell and Ivan Morrison 
 The role of cross-presenting dendritic cells in priming protective CD8 T cell responses – 
Charlotte Bell and Ivan Morrison 
 Use of a peptide library for antigen screening – Charlotte Bell and Ivan Morrison 
 Bovine MHCI typing by Illumina NGS – Tim Connelley and Ivan Morrison 
 Tetramer and TCR analysis – Tim Connelley and Ivan Morrison 
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Background 
Due to high mortality and morbidity rates livestock diseases are an impediment to the livelihoods of 
poor farmers in Africa, who struggle to attain food and nutritional and economic security. Vaccines 
can alleviate such constraints as they are among the most successful disease interventions invented. 
The goal of this project is to increase cattle productivity through the development of improved 
vaccines for the control of East Coast fever (ECF). 
 
ECF caused by the protozoan parasite Theileria parva ranks first in tick-borne disease constraints of 
cattle in sub-Saharan Africa and kills one animal every 30 seconds. It has a devastating impact on 
pastoralists and smallholder farmers because it can kill within 3-4 weeks of infection. ECF is present 
in 11 countries where roughly 28 million cattle are at risk, but has the potential to spread with the 
uncontrolled movement of infected cattle as the distribution of the tick vector and suitable tick 
habitats is wider than that of the parasite. Over one million cattle die of ECF each year resulting in 
annual losses exceeding $300 million. 
  
Our goal is to design subunit vaccines for the control of ECF. In phase 1, we proposed a range of key 
strategic activities in the research to product development continuum to: 
 
 Improve aspects of the current sub-optimal live (infection and treatment method - ITM) ECF 
vaccine. 
 Fill knowledge gaps regarding the qualitative and quantitative aspects of acquired immune 
responses that mediate immunity to ECF. 
 Test the vaccine potential of candidate vaccine antigens and develop a more detailed 
antigen map. 
 
Outputs from this phase will contribute in the short-term to production of a better quality live 
vaccine as an interim vaccine solution and provide proof-of-concept for an ECF subunit vaccine 
aimed at obtaining evidence of protection in 70~80% of animals of defined MHC genotype given a 
homologous parasite challenge. Success in phase 1 will contribute to our goal of developing a broad-
spectrum subunit vaccine for the control of ECF (phase 2). 
 
In order to achieve these objectives we have assembled a team of multi-national experts from the 
field of ECF research, bovine immunology, parasitology and genomics with essential inputs from a 
private-public partnership and the private sector. An advisory panel will provide scientific oversight 
and help evaluate progress and stop-go decisions. This panel will interact with a project 
management committee to ensure that technical risks are reduced and activities are completed or 
re-directed in a timely manner, within budget and that maximum advantage is taken of knowledge 
and learning generated during the project. 
 
ECF activities are also funded by the Normal Borlaug Commemorative Research Initiative (NBCRI) 
and the CGIAR Research Program on Livestock and Fish. 
 
Objectives of the meeting 
1. Review the past 12 months, products, results delivered 
2. Plan the next 36 months, products, deliverables 
3. Get inputs from the External Advisory Committee and Funding agencies 
4. Propose improvements to consortium operation 
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Session 1 – Introduction 
 
The 2015 Annual ECF Consortium workshop was held at ILRI-Addis Ababa from 9-11 January 2015. 
The ILRI campus provided an excellent environment for formal workshops and a relaxed atmosphere 
for post-workshop discussion and debate. This was a second meeting of the Consortium but the first 
one with the expanded membership due to additional activities sponsored by the supplemental 
funding from DFID.  
 
The opening session by Vish Nene outlined the objectives of this meeting, to: 
1. Review the past 12 months, products, results delivered 
2. Plan the next 36 months, products, deliverables 
3. Get inputs from the External Advisory Committee and funding agencies 
4. Propose improvements to consortium operations. 
 
The presentation reminded Consortium members of the genesis of the project, its structure and 
management.  
As the scope of some activities had changed and new ones added it was necessary to review the 
Results Framework and working budgets. It was necessary to catch up on the science, discuss 
problems and tentative solutions, and learn from what worked and did not work during the last 12 
months.  
 
While communication between different groups had improved, this remained an issue that could be 
improved, including how to make better use of the External Advisory Committee. This was the first 
meeting of the Consortium with the new Senior Program Officer from BMGF, Nick Juleff.  
 
Based on comments from the last Consortium meeting, we decided on a different format for this 
one, including use of a Facilitator, Peter Ballantyne, which proved to be a great success. The heart of 
this was reporting and discussing the science in a series of short 5~10 min presentations followed by 
group discussion, debate and consensus building.  Beyond the science, the program also provided 
self-organized ‘workshops’ on different topics of shared interest as well as some plenary space to 
reflect on some overall directions in the consortium.   
 
On the last morning, the program management team met comprising project leaders and members 
of the External Advisory Committee. The notes and actions from that meeting are included in this 
report. 
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Session 2 – Review of 2014 science 
During the meeting, teams working on different activities gave brief presentations (5 minutes). 
These were followed by intensive group discussions and Q&A. Presenters were asked to focus on: 
Main activities in the past year; Key results and deliverables in the past year; New insights gained; 
and plans or the coming year.  
 
Here we include notes that were received for some sessions. Here there are no note, please contact 
the session presenters indicated. 
 
Re-assessment of the sporozoite p67 molecule as a candidate vaccine antigen 
– Anna Lacasta 
 
A. Why is this piece of research being done and what is its contribution to the challenge 
‘Developing Improved vaccines for the control of ECF in cattle in Africa’? 
 
Sera from cattle in ECF endemic regions contain sporozoites-neutralizing antibodies that target a 
surface molecule called p67. This molecule induces weak antibody responses during the ITM, but 
immunization of cattle with recombinant p67 induces neutralizing antibodies and immunity to ECF in 
50% of vaccinated cattle under laboratory conditions. Interestingly, an 80 amino-acid section called 
p67C gives the same level of protection as the whole p67.  
 
Unfortunately, the immunity to ECF achieved was not correlated with the titers of antibodies or even 
the neutralizing activity of those antibodies. We will improve the antibody neutralizing assay to allow 
determining the neutralizing capacity of the archived sera samples and find a correlation between 
the immunity achieved and the antibody activity.  
 
B. Briefly, what research was actually done, who by, and what were the key results/insights in 
2014? 
 
Re-assessment of p67C  
An in vivo experiment was done dividing the animals in three groups. In group 1 (G1) we placed 12 
control animals that were not immunize, in group 2 (G2) the 11 animals who received 2 
immunizations of 450 μg of p67C mixed with Montanide ISA206 adjuvant (expressed in E. coli and 
purified with Ni+ column, 99% purity) and in group 3 (G3) the 11 animals who received three 
immunizations of the same p67C protein. The immunizations where administered every 4 weeks and 
three weeks after the last immunization all animals (G1, G2 and G3) where challenged with an LD70 
dose of T. parva Muguga 3087.  
 
The last results using p67C (10 years ago) were confirmed in this experiment. G3 animals (three 
immunizations) achieved a 50% reduction in severity, being the only group with a significant 
protection achieved (p=0,022). G2 (two immunizations) doesn’t have a significant reduction in 
severity even though the severity was reduced 30%. With this p67C formulation we cannot reduce 
the number of doses from three to two, because the protection achieved is not the same.  
 
Sera, PBMCs, whole blood samples were collected every week and stored appropriately. Sera 
samples were analyzed in an ELISA using p67C recombinant protein as a coating antigen and anti-
IgG/M: HRP as a secondary antibody. All sera were serial diluted from 1/11,11 to 1/24300 (3 fold 
dilution every time). A CD4+ proliferation assay was also done with fresh cells using p67C 
recombinant protein as stimuli.  
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In both assays (proliferation and ELISA) we observed that the animals in G3 have the highest titers of 
antibodies and CD4+ cells against p67C recombinant protein in average. This result correlates with 
the protection achieved in this group. Unfortunately, we were not able to correlate individually.  
 
People involved: Anna Lacasta, Stephen Munyao, Elias Awino, Rosemary Saya, Charity Muthoni, 
Benjamin Nzau, Thomas Njoroge, Roger Pelle and Lucilla Steinaa.  
 
Seroneutralization assay 
The new seroneutralization assay is based on: briefly, mix the sera (different dilutions) and the 
sporozoites (same batch every time) and incubate for 1 h. After dispense the mix on a PBMCs culture 
and incubate for 10 days. Finally the read-out of the assay will be done by a cellular ELISA using anti-
PIM antibody to detect infected cells (96-well plate). 
 
In order to develop this new seroneutralization assay there was the need to establish the highest 
dilution where the 100% of the wells are infected. During 2014 this dilution was established in 
1/1280 using the T. parva Muguga 3087 stabilate #4235.  
 
The anti-PIM (clone ILS32.2) cellular ELISA was confirmed as a good read-out assay using TpM cells 
as a source of infected cells. It was possible to detect as less as 10 infected cells with this method. It 
is need to improve a bit the technique but it looks like we are going to implement this method as a 
final read-out of the new seroneutralization assay.  
 
C. In terms of this piece of research, what are your plans for 2015-2016 (and who will be 
involved)? 
 
Re-assessment of p67C  
 Test all the sera from the re-assessment of p67C expeiment in a p67C recombinant protein 
ELISA using different isotypes: IgG1, IgG2, IgG and IgM (people involved: Anna Lacasta, 
Stephen Munyao, Benjamin Nzau and Charity Muthoni). 
 Test all the sera in a native p67 ELISA using a capture ELISA and using different isotypes IgG1, 
IgG2, IgG and IgM (people involved: Anna Lacasta, Stephen Munyao, Benjamin Nzau and 
Charity Muthoni). 
 Test all the interesting sera with the new seroneutralization assay (people involved: Anna 
Lacasta and Stephen Munyao). 
 New formulation with p67C to make it more immunogenic: TMV-p67C, slow-release beads 
with p67C… (people involved: Anna Lacasta, Stephen Munyao, Charity Muthoni, Thomas 
Njoroge, Roger Pelle and Lucilla Steinaa). 
 Re-assess p67C protein in an LD100 experiment with exotic breeds (Anna Lacasta, Stephen 
Munyao, Thomas Njoroge, Roger Pelle and Lucilla Steinaa).  
 
Seroneutralization assay 
 Look for a bovine T-cell line in the literature and/or immortalize T-cells.  
 In parallel work with ConA blast to homogenize the cell culture in the assay. 
 Test all the possible positive controls for the assay: AR22.7, AR21.4, 23F, TpM… 
 Do the anti-PIM cellular ELISA in a real infection to validate the assay. 
 Switch to ILS40 (anti-PIM) antibody to homogenize the reagents with the other members of 
the Consortium.  
 
D. What were the most significant questions/issues/challenges/feedback that came up in your 
bus stop, and how are they big addresses (if applicable)? 
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Re-assessment of p67C  
 Look for individual correlation between the protection achieved and the antibody titers or 
activity:  
o Suggestion from the Bus Stop: Use a different antigen for the ELISA, ideally use the 
native p67 protein using a capture ELISA.  
o Suggestion from the Bus Stop: maybe there is some reaction against the His-Taq, 
check it doing the ELISA with another protein containing the His-Taq. 
o Suggestion from the Bus Stop: look at the different isotypes.  
 There is no boost in antibody titers or CD4+ proliferation index after the challenge and the 
antibody titers in general are not high. 
o Suggestion from the Bus Stop: maybe re-challenge the animals to see if then there is 
a boost. 
o Suggestion from the Bus Stop: look until when is possible to detect antibodies 
against p67C without challenge or after the challenge.  
o Suggestion from the Bus Stop: reduce the antigen dose, in Malaria field too much 
antigen is not working.  
o Suggestion from the Bus Stop: try to find a new formulation that makes the p67C 
protein more immunogenic.  
o Suggestion from the Bus Stop: go for the full length p67 protein now that we have 
more tools for expression (yeast).  
 LD70 dose is problem to find correlations because we have one non-reactor in the control 
group. 
o Suggestion from the Bus Stop: use an LD100 
o Suggestion from the Bus Stop: re-analyze the data removing the non-reactor animals 
 Three are too many immunizations. 
o Suggestion from the Bus Stop: try to find a system that allows fewer immunizations 
achieving the same level of protection. Maybe the use of BSA particles? 
o Suggestion from the Bus Stop: use of inactivated or dead sporozoites for vaccination. 
 
Seroneutralization assay 
 No availability of a Bovine T-cell line: 
o Suggestion from the Bus Stop: try to work with ConA blast 
o Suggestion from the Bus Stop: create it de novo, immortalizing the cells transforming 
them with a specific plasmid construction 
 How to make it quantitiative:  
o Suggestion from the Bus Stop: do sporozoite dilutions a part from the sera dilutions 
 Need of good positive control:  
o Suggestion from the Bus Stop: use of different monoclonal and/or polyclonal 
antibodies: AR22.7, AR21.4, 23F, TpM… that we have in house (ILRI) 
 Anti-PIM cellular ELISA not tested in a real infection  
o Suggestion from the Bus Stop: do the anti-PIM cellular ELISA in a real infection with 
the selected cell lines or fresh PBMC as soon as possible to validate the technique 
 Anti-PIM used in the assay (ILS32.2) is not the one that the Consortium is using for another 
assays (ILS40). 
o Suggestion from the Bus Stop: switch to the ILS40 to see if it also works efficiently. If 
it works just use this one. 
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Immunization studies with PIM and characterization of sporozoite ligands 
and host cell receptors that mediate the infection process – Ine de Goeyse 
 
A. why is this piece of research being done and what is its contribution to the challenge 
‘Developing Improved vaccines for the control of ECF in cattle in Africa’? 
 
The Hepatitis B core antigen (HBcAg) is a self-assembling particle and is an excellent carrier for the 
presentation of heterologous epitopes. Although well-defined CD4+ T helper epitopes are present, 
the particle can also act as a T cell independent antigen and immunogenic responses are induced 
without adjuvant help. Insertions between residues 77 and 78 in the immunodominant loop region 
induce optimal antibody production, which makes this carrier interesting in the production of an 
anti-sporozoite vaccine. 
  
B. briefly, what research was actually done, who by, and what were the key results/insights 
in 2014? 
 
Possible epitopes of PIM were selected and also p67C was chosen to insert in the HBcAg gene. 
Primers were developed at ITM Antwerp and first PCRs were completed. All polypeptides were 
cloned in a pGEM-T easy vector and sequenced. By the end of the year, HBcAg-p67C was completely 
finished and sequenced in January 2015. HBcAg-EP1 and HBcAg-EP2 were still under construction.  
  
 C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be 
involved)? 
 
All constructs will be finished and after sequencing, expression will be induced in E. coli cultures and 
checked on SDS-PAGE and Western blot. Expression of the different fusion proteins will be carried 
out on a large scale and proteins will be purified. After purification, correct folding of the particles 
will be evaluated by transmission electron microscopy (TEM). After that rabbits will be used to test 
the immunogenicity of the different particles. All work will be done at ITM Antwerp.  
  
E. what were the most significant questions/issues/challenges/feedback that came up in your 
bus stop, and how are they big addresses (if applicable)? 
 
Are rabbit trials worthwhile? Maybe it’s better to go directly to cattle. The antibody-response of the 
rabbits will tell nothing about the reaction of the cattle. That’s true, but by immunizing just a few 
rabbits, we know that the inserts are expressed well and patent to be recognized by the immune 
system. Unless the fact that PIM is not on the sporzoite surface, anti-PIM antibodies might still be 
able to block off the sporozoite entry in the lymphocytes. One of the leading antigens in the Malaria 
research is also not present at the surface. We still have no idea about the structure and the 
function of PIM… 
  
Antibodies to define novel candidate sporozoite vaccine antigens – Lucilla 
Steinaa 
 
This work was/is done by members of the ILRI ECF team: Anna Lacasta, Lucilla Steinaa, Roger Pelle, 
Benjamin Nzau, Stephen Munyao, Vish Nene. 
 
To date, P67 is the only discovered antigen to which a humoral immune response has shown 
efficiency. Using more modern approaches it may be possible to discover other sporozoite antigens 
involved in the entrance of the parasite which could be possible vaccine candidates.  
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Nine vaccine candidates have been selected based on orthology with other apicomplexan parasites 
and one based on CD homology. Expression has been outsourced to GenScript. 4 have been 
produced and the other 6 are underway. Antisera will be produced and tested in neutralization 
assay. 
 
Sporozoites were successfully stained and analyzed on the Influx sorter. Costaining with antisera 
against tick salivary gland material will be attempted and pure sporozoites will be sorted for 
immunization of mice and cattle for production of antibody libraries, which then will be tested in 
neutralization assays. 
 
Plan for 2015-2016 is to get the rest of the orthologous molecules produced, generate sera and test 
in neutralization assay. Sort pure sporozoites, immunize mice and cattle, produce libraries and test 
in neutralization assay. 
 
Responses at bus stop: It was mentioned, from the Malaria field, that there were additional new 
orthologous antigens which may be pursued – something we can look at. 
 
Genomic based method to dissect bovine antibody responses 
 
For further information contact Roger Pelle 
 
Recombinant antibodies – Fred Fellouse 
 
A key hurdle in the development of vaccines is the inability to discern protective from non-protective 
immune responses. Having a set of antibodies to characterize the bovine immune response would 
help us address this challenge and recognize true protective immune responses. Goal: To generate a 
set of antibodies to characterize the bovine T cell-mediated immune response. Update: We have 
purified two highly relevant bovine cell surface CD antigens and generated recombinant antibodies 
against these antigens for flow cytometry, immunoprecipitation, and other applications. One 
antibody will soon be validated at the University of Edinburg. Next steps: Identification of other 
bovine antigens to be targeted for affinity reagent development; generation and validation of novel 
affinity reagents for bovine immunology applications. 
 
Part of the consortium’s strategy is to identify antigens that would enable production of neutralizing 
antibodies against the sporozoite form of T. parva.  
Goal: We will be using phage display technology to identify natural and synthetic neutralizing 
antibodies in order to (1) screen the antigen candidates for their ability to generate neutralizing 
antibodies (2) generate antibodies that could be used by the consortium as research reagents or 
vaccine adjuvants. Update: The generation of specialized synthetic antibodies under way. Next 
steps: Use the synthetic antibody libraries developed at the University of Toronto to generate 
neutralizing antibodies; develop and test novel synthetic antibody libraries tailored to targets of 
interest, in particular novel antigens identified by the “novel sporozoite antigen discovery” focus 
group. 
 
p67 peptide chips and epitope mapping - Soren Buus 
 
A. why is this piece of research being done and what is its contribution to the challenge ‘Developing 
Improved vaccines for the control of ECF in cattle in Africa’? 
We will be using the peptide-chip technology to to a large-scale screening for novel (sporozoite) B 
cell antigens.  
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B. briefly, what research was actually done, who by, and what were the key results/insights in 2014? 
  
Nothing has been done on this part of the project in 2014, but we have applied the technology 
earlier in other project with high success. In particular have we demonstrated how the technology 
can be used to identify novel antigens for Chagas disease using sera from infected patients.  
  
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be involved)? 
  
We will define what T.parva proteins to analyze on the chip (other than p67). Define what type of 
sera to use to screen the chip (sera from ITM vaccinated cattle after a different number of 
vaccinations?, sera from infected cattle versus sera from infected buffalo?, …). Once these issues 
have been resolved, we will construct a peptide chip covering the selected proteins, and assay the 
chip with the selected sera.  
 
People involved in this are the focus group 3 (and to some extend focus group 2)  
 
D. what were the most significant questions/issues/challenges/feedback that came up in your bus 
stop, and how are they big addresses (if applicable)?  
  
The most important questions that came up at the Bus stop related to the issues described above 
(definitions of protein and sera). 
  
Improve the ITM production process - Dirk Geysen 
 
A. why is this piece of research being done and what is its contribution to the challenge ‘Developing 
Improved vaccines for the control of ECF in cattle in Africa’? 
 
 This is an update on the first batch of vaccine production at CTTBD. ITM (Infection and 
treatment Method) is the only vaccine approach controlling ECF in the field in Kenya, 
Tanzania and Zambia for the moment. This is based on injecting a titrated dose of live 
cryopreserved sporozoites under the cover of long acting Terramycine. Efficiency and 
efficacy in the production process needs to be improved. 
 
B. briefly, what research was actually done, who by, and what were the key results/insights in 2014? 
 
 The first batch at CTTBD has been produced using the ILRI protocol. For the second batch 
currently under production, glycerol has been replaced by sucrose. This will improve 
production and facilitate in vitro testing of the vaccine in cell cultures. A change in the pick 
up protocol resulted in better tick infection rates, and a change in the 2 stage release 
procedure will reduce the time to release. 
 
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be involved)? 
 
 Storage of diluent in plastic versus glass bottles to ease distribution problems under field 
conditions Dose reduction as requested by the field, still using 0,5 ml straws but with diluted 
stabilate to accommodate 5 or 10 doses. 
 New diluent tests to increase viability of sporos after thawing in the field. 
 Looking at alternative diluent constituents to reduce price. 
 Grinding optimalisation to increase sporozoite yield, and transfer protocol to new grinder 
equipment (heads and motor). 
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 Molecular characterization of isolates and field samples using 5 antigen genes and 5 mini 
sats. This exercise is intended to analyze the epidemiological situation and field strain 
composition in ECF areas not under Muguga cocktail vaccination. 
 
D. what were the most significant questions/issues/challenges/feedback that came up in your bus 
stop, and how are they big addresses (if applicable)? 
 
 Possibility of adherence of sporozoites to plastic as experienced in grinding plasmodium 
sporos. 
 Release of new stabilate production protocol as to standardize production of research 
stabilates by other groups. 
 Characterisation of vaccine components. 
 Cross immunity tests 
 
Generation of a genome wide locus specific map of genetic variation of T. 
parva 
 
For further information contact Joana de Silva 
 
Determining sporozoite counts – Ine de Goeyse 
 
A. why is this piece of research being done and what is its contribution to the challenge ‘Developing 
Improved vaccines for the control of ECF in cattle in Africa’ ? 
 
A method to quantifiy sporozoites and to distinguish between live and death sporozoites would be 
really helpful to improve the stabilate production process. The Guava easyCyte 5HPL is a cell counter 
with fluorescent detection and can discriminate cell particles between 0.19 µm and 1 µm.  
  
B. briefly, what research was actually done, who by, and what were the key results/insights in 2014? 
 
So far, all tests were done on a glucose stabilate of sporozoites. A staining protocol was optimized 
for monoclonal antibodies directed against sporozoite antigens. Sporozoites can be stained with 
anti-p67 monoclonal. Different viability dyes were tested: Mitotracker (living cells), PI (dead cells), 7-
AAD (dead cells), FDA (living cells), Zombi Green (living cells), but none of them gave the expected 
results so far. 
  
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be involved)? 
 
The protocols will be performed on sporozoites extracted from new infected ticks, and compared 
with the sporozoites from the stabilates. Other dyes will be checked for viability staining. By the end 
of the year the Guava easyCyte will be shipped to CTTBD in Lilongwe, Malawi, where it will be used 
in the ITM production process. 
  
 D. what were the most significant questions/issues/challenges/feedback that came up in your bus 
stop, and how are they big addresses (if applicable)? 
 
Maybe the sporozoites have no or low metabolic activity. Are there any biological assays for 
live/dead staining? 
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Development of a tick challenge model 
 
For further information contact Glen Scoles 
 
Use a genomics approach to prioritize genes as candidate vaccine antigens 
 
For further information contact Joana de Silva 
 
Characterize the magnitude, kinetics and functional profile of the protective 
T cell response 
 
For further information contact Tim Connelley 
 
Assess the requirements for induction of a protective T cell response  
 
For further information contact Ivan Morrison 
 
Identify additional CD4 antigens and phenotypic data on ECF - Lindsay Fry 
 
A. why is this piece of research being done and what is its contribution to the challenge ‘Developing 
Improved vaccines for the control of ECF in cattle in Africa’? 
 
 The antigen discovery portion of this work is being done to find CD4+ T cell antigens to 
include in a recombinant vaccine. This is necessary because, in general, strong CD4+ T cell 
responses are necessary for adequate priming of CD8+ T cells. The work to characterize the 
immune response within the actual tissue of acutely infected cattle is being done to broaden 
our understanding of what happens in the cow during disease – e.g. dissect out appropriate 
and inappropriate (harmful) aspects of the response. This is being done in the hope that 
vaccine design will minimize these harmful aspects of this response and to promote a more 
appropriate, protective response in cattle. 
 
B. briefly, what research was actually done, who by, and what were the key results/insights in 2014? 
 
 Lindsay Fry, Don Knowles, Glen Scoles, Wendy Brown: We established the full T. parva 
infection cycle in Pullman, WA, and generated infected cattle and ticks, and a sporozoite 
stabilate. 
 
 Lindsay Fry, Don Knowles, Joana Silva, Wendy Brown: We used in-silico prediction to select 
113 candidate T-cell antigens based on predicted conservation and secretion. We ordered 
peptides that span those antigens (910 peptide pools), to be screened in the upcoming year 
using T cells from immune cattle.  
 
 Lindsay Fry, Don Knowles, Ivan Morrison: We performed histopathology on tissues from 
deceased animals and discovered that T. parva causes vasculitis within the lungs, lymph 
nodes, liver, and spleen, and that this vasculitis is what leads to pulmonary edema and death 
in cattle with ECF. 
 
 Lindsay Fry, Don Knowles, Wendy Brown: We used immunohistochemistry to begin to 
characterize the immune response in acutely infected animals. We discovered that 
pulmonary pathology is likely due to an overly robust IL-17 response, and that acute lesions 
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are infiltrated by large numbers of immunosuppressive T cells, which may severely 
exacerbate disease and suppress T cell function. 
 
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be involved)? 
 
 We will screen the 910 peptide pools using T cells from immune cattle to discover potential 
CD4+ T cell antigens for inclusion in a vaccine (Lindsay Fry, Don Knowles, Wendy Brown) 
 We will finish characterizing the immune response in tissue from acutely infected cattle 
(Lindsay Fry, Don Knowles, Wendy Brown) 
 
D. what were the most significant questions/issues/challenges/feedback that came up in your bus 
stop, and how are they big addresses (if applicable)? 
 A significant challenge is MHC class I typing of cattle using allele-specific PCR. We have 
begun work with a collaborator to use deep-sequencing, and plan to evaluate that method 
throughout the year. 
 
 
Evaluate Ad5/MVA antigen delivery systems – Nicholas Svitek 
 
Comments: 
- Verify if the lower responders are the survivors (weaker response would correlate with 
survival). 
- There might be a short window of time when measuring ex vivo cytolytic activity (between 
9-12 days).  
Questions raised: 
- Can we increase/force a Tp1-specific response by using viral vectors expressing stretches of 
the Tp1 epitope aligned together (poly-Tp1 epitope sequence)? 
- What are the other correlates of protection? 
- Is the TCR-p-MHC avidity the same in viral vector-vaccinated animals as in ITM-vaccinated 
animals? 
- Can the route of immunization influence the quality of the immune response generated 
(sub-cutaneous or intra-dermal route would put the antigen in proximity with Langerhans 
cells)? 
- Do the high responding CD8 cells differentiate into a specific function/phenotype (are they 
mono- or polyfunctional)? 
- Why is there no lysis of TpM? 
- Can we increase protection by adding CD4 T cells antigens (they are more promiscuous 
antigens) and B cell antigens? 
Suggestions/Ideas: 
- Challenge: perform a challenge experiment in cattle vaccinated with p67 and HAd5/MVA-
Tp1 
- Perform cytotoxicity assay with whole blood cells and spiking with the CTL raised in vitro (are 
there other factors from the blood that we miss in the CTL assay; measuring lysis with all 
cells around?) 
- Add other cell populations in the ELISpot assay (Natural killer cells, etc.). 
- Should we perform a third boost and see how it increases responsiveness/protection? 
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- Compare lung pathology between animals with CD8 and animals without or lower CD8 
response (link with Lindsay’s work). 
- Stimulate CTLs in vitro with TpMs inactivated by paraformaldehyde (can it diminish 
immunosuppression activity of TpMs on CTLs?). 
- If performing a tick-challenge, do we have a more natural level of infection and hence a 
better protection (is the LD100 to strong)? 
 
Evaluate a BHV antigen delivery system 
 
For further information contact Don Knowles 
 
Use of heat shock proteins for induction of CTL immunity 
 
For further information contact Roger Pelle 
 
CTL-induction: adjuvant and reagents – Lucilla Steinaa 
 
This work was done by members of the ILRI ECF team: Lucilla Steinaa, Roger Pelle, Nicholas Svitek, 
Rosemary Saya, Elias Awino, Stephen Munyao, Vish Nene. 
 
A study was undertaken to elucidate if two A18 BoLA allelic variants (6*01301 and 6*01302) both 
present the Tp1 antigen. It was mandatory to determine this because presentation of Tp1 has been 
reported for 6*01301 but not for 6*01302 and the latter is the most prevalent allele in Kenyan cattle 
and because we are using Tp1 as a model antigen. The conclusion was that there was no difference 
found between the two alleles regarding presentation of Tp1 for CTL induction so both alleles can be 
used for vaccine studies. 
 
Further, we know that CTL is important in the immune response against T. parva but there is not a 
good adjuvant/delivery system for induction of CTL in large animals and humans. An adjuvant from 
Statens Serum Institut (DK) was tested for induction of CTL in cattle when mixed with the Tp1 
protein. This adjuvant should supposedly be capable of inducing cellular responses. However, CD8 
cells were not positive in IFNγ ELISPOT and tetramer assay and CTL assay were negative. 
 
Plans for 2015 are to test an alpha-virus platform from Harris Vaccines (US) using the Tp1 antigen. 
This system gives expression in the infected cells but it doesn’t produce infectious virions and hence 
it does not spread. We will also test Silica based nano-beads in collaboration with University of 
Queensland (AU) in 2015.  
 
Responses at the bus stop were: What other delivery systems will you try? Answer is that apart from 
these and the Adhu5/MVA we have some other ideas in the pipeline that we will pursue. 
 
Yeast expression systems and the RVC activities – Dirk Werling 
 
A. why is this piece of research being done and what is its contribution to the challenge 
‘Developing Improved vaccines for the control of ECF in cattle in Africa’ ? 
 
Developing new ECF vaccine delivery tools that can be stored at room temperature. 
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B. briefly, what research was actually done, who by, and what were the key results/insights in 
2014? 
 
Dr Shan Goh cloned several Theileria parva proteins in such a way that these can be expressed in the 
platform delivery system  
 
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be 
involved)? 
 
The resulting delivery systems will be tested in vitro for their ability to stimulate a CTL as well as CD4 
response. This work will be done by Dr Shan Goh and Daniel Ngugi  
 
D. what were the most significant questions/issues/challenges/feedback that came up in your 
bus stop, and how are they big addresses (if applicable)? 
 
Everyone thought it is a really great idea – especially if it works. 
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Session 3 – Workshops 
Alongside the science results reported in Session 2, participants formed groups to discuss cross-
cutting topics. The aim as to: 1) take stock what is happening in the consortium and 2) identify 
specific activities or actions for the consortium. As with the science sessions, reports of some 
sessions are included in these notes. 
 
 
ECF index and LD70/LD100 challenge – Tim Connelley 
 
The aim of the workshop was to discuss two related but distinct issues 
 ECF index – the statistical scoring system used to determine the severity of a response to 
challenge with T. parva stabilate.  
 LD70/100 – the dose of a T. parva stabilate used to challenge immunised animals has either 
been LD70 (i.e. sufficient to kill 70% of animals) or LD 100 (i.e. sufficient to kill all animals). 
Which dose is most appropriate for use in forthcoming experiments? 
ECF index 
 There was general agreement that the Rowlands Index was labour intensive and difficult to 
implement due to the increased regulatory requirements for limiting the times that animals 
exhibiting signs of ill health can be maintained under experimental conditions.  
 Analysis by Lucilla and Nick using a modified Rowland’s scoring system (so-called ‘Scotland 
score’) demonstrated that it was conceivable that a more simplified version of the Rowland’s 
index could be established and would prove useful. The ‘Scotland score’ removed the 
‘length’ parameters in the Rowland’s index and focused primarily on the ‘first day’ scores. 
 Data from Nick and Lucilla suggested that using WBC, temperature and schizont parameters 
it was possible to segregate none/mild, moderate and severe responders by d14. 
 Tim suggested that more quantifiable schizont scoring could be achieved by using an IFAT 
system incorporating anti-schizont antibody and DAPI staining (for nuclear material) to 
provide a numerical percentage of schizont/bovine nuclei. This staining system also provides 
a double staining for schizont as DAPI stains schizont nuclei also (as small and punctate 
clusters of nuclei co-localising with the schizont antibody) and is routinely used at both 
Roslin and WSU. Additionally IFAT was more rapid to analyse, less technically demanding 
and more sensitive than giemsa staining. Incorporation of a quantifiable schizont count may 
also make it a more refined parameter within any modified ECF index scoring system. 
 It was agreed that a revised system that reduced the amount of work and gave a score based 
on measurements taken earlier post-challenge should be devised. To achieve this it would 
be good to amalgamate recent raw data from ILRI, Roslin and WSU and submit it to 
statistical analysis. Tim is to initially approach Helen Brown (who generated the ‘Scotland 
score’) to see if she is willing to lead this work in cooperation with Jane Pool at ILRI and then 
seek for the data to be sent from ILRI, WSU and Roslin. 
 
LD70/100 
 This discussion was unfortunately curtailed by time limits. 
 Lucilla discussed that although there was some preference at ILRI for LD70, its use would 
require unfeasibly large numbers of animals to compensate for the reduced statistical 
power. 
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 Nick showed some data that looked at the effect of stabilate dose and LD values that 
indicated that small dilution factors (2-4 fold) were sufficient to reduce an LD70 to an LD40. 
 Tim and Ivan from Roslin indicated a preference for LD100 as all ITM animals were 
comfortably protected from this dose. Furthermore, at Roslin the increase in animals 
required to accommodate an LD70 dose is not practical. 
 It was generally concluded that experiments would use an LD100, with perhaps secondary 
experiments to explore further promising candidates utilising a LD70.  
p67 way forward and other sporozoite antigens 
 
For further information contact the organizers – Ana Lacasta and Roger Pelle 
 
Sporozoite purification, quantification and ITM 
 
For further information contact the organizers – Ine and Dirk 
 
Computational resources 
 
For further information contact the organizers – Joana and Morten 
 
Peptide proteomics and BoLA reagents 
 
For further information contact the organizer – Soren Buus 
 
Peptide proteomics - Nicola Ternette 
 
A. why is this piece of research being done and what is its contribution to the challenge ‘Developing 
Improved vaccines for the control of ECF in cattle in Africa’? 
 The identification of novel T-cell antigens in T.parva infection using mass spectrometry 
provides the basis for the development of new vaccination strategies. 
 
B. briefly, what research was actually done, who by, and what were the key results/insights in 2014? 
 In a single proof of concept pilot experiment with Ivan Morrison and Tim Connelley with the 
help of Joanna da Silva we have demonstrated the ability to perform MHC class I elution of 
Theileria infected bovine cells, with the identification of >2000 bovine peptides and >50 
matching peptides predicted from a 6-reading frame translation of the T. parva genome. In 
order to control for false-positive identifications, a second control experiment of uninfected 
cells was performed and analysed under the same conditions. Additionally, further careful 
evaluation of obtained sequences assisted by BLAST searches (http://www.ncbi.nlm.nih.gov/) 
was conducted to exclude identifications with high sequence similarities to other 
mammalian genes. 
 
C. in terms of this piece of research, what are your plans for 2015-2016 (and who will be involved)? 
 More samples with different MHC backgrounds will be analysed and regarding control 
experiments will be optimized. Validation procedures for identified peptide sequences will 
be implemented. This will include MHC binding studies with Soren Buus, bioinformatical 
prediction of epitope processing and binding with Morten Nielsen, and analysis of existing T 
cell responses in infected animals with Tim Connelley. 
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D. what were the most significant questions/issues/challenges/feedback that came up in your bus 
stop, and how are they big addresses (if applicable)? 
 Analysis of sporozoite proteins directly using mass spectrometry could potentially provide 
novel antigens for a B cell based vaccination approach as well. 
 
 
Antigen delivery systems / correlation with CTL 
 
For further information contact the organizers – Ivan Morrison and Lucilla Steinaa 
 
Reagents, protocols, MHC typing, peptides/proteins and viral vectors – Tim 
Connelley 
 
Reagents 
1 - monoclonal anitbodies 
 List of available monoclonal antibodies ‘in-house’ to be made. It was initially decided that 
this would be done by Tim (Edinburgh), Rosemary and Nicholas (ILRI), Lindsay (WSU) but this 
may now depend on decisions made by the reagents focus group. There was discussion of 
generating a comprehensive list of commercially available antibodies including ELISA kits 
 Request by Don for list of known anti-p67 antibodies. Anna and Ines to email Don. 
 Fred also made reference to the potential cross-reactive potential of antibodies generated in 
Toronto and that this may be worth having a list available as part of the database being set 
up by the reagents focus group. 
2 – tetramers 
 List of currently available MHCI heavy chains and the associated epitopes to be requested 
from Soren/Nicholas by Tim. This will then be made available through the schizont antigen 
discovery focus group and also the reagents focus group. 
3 – cell-lines 
 Ines requested a list of available cell lines. Discussion of what this is to include: Theileria-
infected cell lines, CD4/CD8 anti-theileria cell lines, MHC-transfected cell lines. Also 
discussion of the characteristics that would need to be defined (e.g. for Theileria infected 
cell lines – MHCI/II type, phenotype (T-cell or B-cell etc.), strain infected with, antigenic 
variants etc.). Some initial list could be made but may need more discussion as part of the 
reagents focus group. 
4 – sera 
 Anna recommended a databank of sera be generated. This may need further consideration 
from people directly involved in anti-sporozoite immunity work to define the best format 
this would take and what information would be needed for each sample. Again probably 
best now referred to the reagents focus group. 
5 – Other reagents 
 It was decided that primers may be too numerous to form a database for – instead it made 
be easier if someone needs primers for a specific gen they send a general request out to a 
‘laboratory techniques’ email list to be set up as part of the reagents focus group. 
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Action points 
Location Person Action Deadline 
1 – should be 
done asap 
2 – delay until 
discussed by 
reagents focus 
group 
Edinburgh Tim List of available monoclonals 
Tetramer list from Soren 
2* 
1* 
ILRI Anna Email Don Knowles list of anti-p67 antibodies 1 
 Nicholas  List of available monoclonals 2 
 Rosemary List of available monoclonals 2 
ITM Antwerp Ine Email Don Knowles list of anti-p67 antibodies 1 
WSU Don   
 Lindsay List of available monoclonals 2 
Toronto Fred List of monoclonal antibodies that may have cross-reactive 
potential for cattle 
2 
 
 
Inter-lab collaboration and sharing 
 
For further information contact the organizers – Lottie 
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Session 4 – SWOT 
In plenary, participants discussed, shared and documented the program’s strengths, weaknesses, 
opportunities and threats.  The point captured are listed below. 
 
What we like in the consortium 
• Exciting science 
• Group interactions 
• ECF research enthusiasm 
• Great technologies 
• General organization of the consortium 
• Recovering and re-assessing historic data 
• Diversity among the team 
• Public attention to ECF is rising = more money 
• High potential to deliver 
• We are getting bioinformatics data to users 
• Collaborations targeted to aims 
 
What we need to improve 
• Communications - internal especially 
• Sharing and harmonizing of reagents/ accessing central resources 
• Providing feedback 
• Prioritization of approaches; potential problem of too many disparate approaches 
• Sharing and shipping can be held back by regulatory issues 
• Yammer 
• Reporting to ILRI 
 
Ways we can improve 
• Monthly sub-group meetings 
• Sharing standard operating procedures (SOPs) ... 
• Specifying ‘go/no-go’ milestones 
• Publish historical data 
• Attend to IP rights 
• Set up an e-forum (yammer?) 
• More consortium involvement when supplementary funding is proposed or acquired. 
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Session 5 – Year 1 synthesis, conclusions and 
recommendations 
 
To synthesize the various presentations and group work, participants re-grouped using a ‘world café’ 
method to document conclusions and recommendations emerging from the past year for each 
consortium objective area. The notes here were transcribed from the group flipcharts. 
 
Objective 1: Improve aspects of the current live infection and treatment 
method ECF vaccine.  
 
Conclusions 
1. CTTBD moved to sucrose in stabilizer for stabilate 
2. Still unable to differentiate live vs dead sporozoites 
3. ECF ITM vaccine diluent will be moved from glass to plastic vials 
4. ECF ITM used as ‘gold standard’ for investigation of immune response in vaccine/challenge 
work 
 
Recommendations 
1. Investigate use of Roland’s index for prediction of clinical outcome post-challenge 
a. Extend broader review for use within consortium 
2. Use GUAVA Antwerp for live versus killed differentiation of fresh sporozoites 
a. Go/no-go needed 
3. Need to decide how geographic strain data will feed into ‘revised’ Muguga cocktail formula 
4. Investigate improved consistency within Muguga cocktail, eg: remove 1 of 3 in Muguga 
cocktail 
5. Greater interaction with Sanaria to learn from irradiation of malaria sporozoites 
6. Investigate salivary gland dissection to increase live sporozoite recovery [Sanaria for freezing 
investigation] 
7. Further search for susceptible continuous cell line for ‘invasion assay’ for quantification (live 
versus dead) 
a. Eileen Thacker to check for transformed bovine T cell line with Jim Roth 
8. Investigate DNA quantification on stabliate, eg: propidrum monoazide [Bitium] or others 
9. Investigate in vitro induction of translation in sporozoites as live versus dead differentiation 
[Sanaria – plasmodium] 
10. Genetic manipulation of sporozoites -> attenuation; over-expression of ‘protective antigens’ 
 
Objective 2: Induce antibody based immunity by targeting the sporozoite 
stage of the parasite 
 
Conclusions 
1. P67C can impart some protective immunity 
2. Neutralisation assay is a priority 
3. Ranking of antigens needs to be done by the end of the project [need platform to prioritize] 
4. P67C -> + control 
 
Recommendations 
1. Improve the delivery of p67C to reduce to 2 injections only 
2. Develop functional assay to predict protection -> down select new antigens 
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3. P67 assay to correlate Ig response with protection 
4. Generate RNA sequence plus protein profiles of sporozoites 
5. Common platform (adjuvants) to evaluate new antigens, also CTL 
6. Find a cell line per NIT 
7. Select antigens for the chips 
8. Generate a hyperimmune sera (multiple animals) 
9. TSG antigen: tick saliva = protein antigens 
10. Choose 1-2 platforms for B cell Ap2(Z?) antigen identification 
 
Objective 3: Induce T-cell mediated immunity by targeting the schizont stage 
of the parasite  
 
Conclusions 
1. We are not convinced about the direct correlation between CTL on its own as an indicator of 
protection but it may still be an important parameter 
2. Viral prime-boost system induces CN8 resistance but not CTL effector function against 
parasite-infected cells 
3. Delivery systems tested so far do not give an adequate protection 
4. The wrong antigens or wrong delivery systems? MUCH DEBATE 
 Majority conclusion: viral delivery system appears defective in its ability to generate 
a response similar to ITM immunization 
5. Need for further work to refine the functional profile of responses induced by vaccine 
constructs and the responses to challenge in comparison to those induced by ITM 
immunization 
6. Standardization of antigens to take forward in the antigen delivery systems to be tested 
 
Recommendations 
1. Compare the response induced by ITM/Cell line vaccination (and compare these) with those 
induced by ‘vaccines’ and recall of responses at challenge 
2. Balance between testing delivery systems and understanding fundamental immune 
parameters of protection 
3. Screening for new antigens 
4. Compare in different strains (conserved, non-conserved 
5. 5 Evaluation of ALL potential delivery systems by end of 2015 
6. Neutralisation assay to finish 
 
 
Objective 4: Apply evolutionary and comparative pathogen genomics to ECF 
vaccinology 
 
Conclusions 
1. Downstream approaches benefitted from re-annotation 
2. Transcriptional analysis of Sp2 material; other life-cycle stages. Also, buffalo vs cattle 
analysis 
3. Establish data sharing platform 
 
Recommendations 
1. How are ‘strains’ identified – need a system? 
2. How are ‘strains’ to be selected – for sequencing? 
3. ‘Strains’ are defined as what? Genetic differentiation 
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4. 12-15 cloned parasites X buffalo [Kenya, rift valley fever, SAfr] ->2mb? 
5. [all these already in ECF bible] 
 
6. Comparison between buffalo and bovine infection 
7. Transcriptome for parasite and host 
8. Data sharing platform [announce when website is up] 
 
9. List of Theileria specific genes 
10. Look for protein families of antigenic significance 
 
11. RNA seq exp. Infected buffalo vs. T. parva-infected cattle. 
12. Measure sequential samples pre-infection, during infecyion [DrLN, Contra LN, immune 
response genes. 
13. Compare IR genes {or whole transcriptonomics) in normal buffalo vs. cattle 
14. Naïve calves? OR? 
 
15. Make sure one common Muguga cloe is used in all labs 
16. Transmission blocking -> why the piroplasm of buffalo is not transmissable 
 
 
Points from the cross-cutting workshops 
 
Conclusions 
1. LD70/LD100 ECF index 
2. p67 should it proceed 
3. Sporozoite purification 
4. Comp. genome database / proteomics 
5. CTL assay / antigen delivery systems 
6. Reagents and protocols 
7. Make more immunogenic p67c and delivery vehicles (systems)  
 
Recommendations 
1. Re-analyze data with statistician and come up with standards in LD70/LD100 ECF index 
 
2. Viral vectors + p67/p67c 
3. Prioritize the identification of new B c ell antigens 
4. Produce fragments of all the part of p67 (better than the full length?) 
5. Make stable full-length 
6. Making multivalent p67 will make it better? TMV 
7. Identification of tick antigen proteins by using immune sera for animals immunized with 
sporozoite tick delivery glands 
8. p67, should it be pursued? 
 
9. Viability and infectivity of sporozoites – sp. purification 
 
10. EUPathDB -> eukaryotic pathogen database (insert data) 
11. Adding sporozoites geneomic/transcriptomic data 
12. Transcriptomics of tick slavery glands 
13. Computational/genomic database 
 
14. HHC-peptides validation [binding prediction, binding assay, T cell response?] Proteomics 
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15. What is the gold standard of CTL measurement? 
16. CD8/CD4 RNA sequencing 
17. Profile of response in ITM immunized animals -> what time point? 
18. CTL assay/antigen delivery system 
 
19. Using standardized SOP to compare, side by side 
20. Using a commercial company to make it easily available 
21. Reagents sharing 
22. Protocols 
23. Using synthetic phage display technology to fast rack generation of new antigens (?) 
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Session 6 – Results framework 
 
This was reviewed 
Several changes were proposed and adopted 
 
 
Session 7 – Vision of success 
 
Exercise 
1. Looking forward one year from now 
2. What does success look like? For you as an individual, for the consortium as a whole? 
3. What are the common elements - of the community, of the platform - that MUST be in place 
for you, for us, to deliver the success? 
 
The information below was captured from group discussions – not validated nor prioritized 
 
Visions of success for 2015 
 
Antigens 
• Identify new CD4 and CD8 antigens 
• Identify sporozoite candidate vaccine antigens by mass-spec 
• Identification of best antigen delivery system for protective CD8 and T cells 
• New T cell antigen identified 
• Yes or no on BHV-4 
• produce enough antigens for vaccine 
• new sporozoite antigens identified and validated 
• immune parameters that correlate with success or failure of schizont antigen immunization 
• Improved antigen delivery system for schizont based immunity 
• One (10) new T and CTL and B cell antigens discovered, including low polymer 
 
Proof of Concept (PoC) 
• Proof of concept P67/TP1 = results 
• Improvement of the P67 vaccine 
• Define the determinants of success/failure 
• Further progress toward vaccine proof of concept 
 
New developments 
• efficient data delivery (flow cytometry/fluorescent microscopy) 
• understand the biology/mechanism of the bovine antibody repertoire 
• new vaccine candidates identified 
• New whole genome assemblies 
• reliable polymorphism estimate 
• the right cell line for the sporozoite assay 
 
Existing ITM vaccine 
• good uptake of the ITM vaccine in the field 
• improved ITM vaccine 
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Common elements needed for success 
Teamwork 
• Happy consortium 
• Effective group interactions and discussions 
• Offering and receiving critical evaluation and feedback 
• Functional focus groups 
 
Working together 
• Sharing reagents 
 
Standards developed and adopted 
• Standard operating procedures 
• Standardization in assay/reagents/read-outs 
• Standardized neutralization assay = permissive cell line 
• Standardized clinical model -> clinical end-points 
 
Budgets 
• Efficient budget burn rate 
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Session 8 – PMC-EAC discussion 
Program Management Committee and External Advisory Council members held a side discussion. 
The agenda proposed was: 
1. EAC Feedback on the work so far 
2. EAC terms of reference 
3. Administrations and budgets update 
4. Structure to manage the consortium 
  meetings 
5. Tapping into other advice 
 
Main conclusions and actions 
1. Make the PMC a real management-oriented group. Draft a TOR for the PMC (more 
management and strategy/oversight focus). Action: Vish Nene. 
2. Establish science 'focus groups' to drive work on different cross-cutting issues and support 
delivery of objectives. Identify list of focus groups and leaders. Action: Flesh out the concept 
during the meeting. Then Vish Nene to follow up. 
• science focus 
• trust-based 
• small (5 people) 
• once a year face to face convening 
• involve outside expertise if needed 
• with a TOR 
• facilitate communications 
• meet virtually (as needed, might be often) 
• perhaps time-bound set up for a specific need 
• report to annual consortium meeting 
• perhaps organize a monthly virtual meetup (in rotation) for any interested folks 
• document work and share to PMC and report to Vish 
3. Ask GALVmed to work on some upcoming policy and regulatory issues. Action: Vish Nene. 
4. Circulate revised EAC TOR. Action: Vish Nene and EAC members. 
5. Explore ways to improve management oversight and delivery and accountability for 
objective 'work packages' - or similar. Action: Vish Nene. 
6. Agree a calendar of meetings and frequency. 
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Action: Establish focus groups 
Below is a transcript of the notes taken by each group. Vish elaborated on some of the scope notes. 
It is expected that as groups meet, these scope notes will evolve. 
 
Group 1: Infectivity assay of sporozoites 
convened by Ine 
 
Scope: Improving the current in vitro infectivity assay 
 
Actions: 
1. Find a plasmid and transform a cell line (please clarify what is meant) 
a. conA cell lines –CD4, CD8, WC1 – adapt them to lower amounts of IL2 and conA 
b. date: June 2015 
2. Test the different stabilates for the chosen cell lines 
a. date: Dec 2015 
3. Cell based ELISA 
a. improve assay by March 2015 
b. ILRI and Antwerp work in parallel 
4. Work on dyes? – try dual labels? If not work, just establish particle counts? 
 
 
Group 2: Immune responses to p67 
Convened by Vish 
(called sp p67 epitope specificity during the Results Framework discussion) 
 
Scope: To define immune correlates with protection induced by p67C  
 
Current status: 2 doses p67C + ISA206 does not protect; 3 doses gives ~50% protection. How do we 
improve this? 
 
Actions: 
1. Define isotypes, avidity, and ?? – to p67C (and native p67?) 
2. Determine neutralizing titers 
3. Map epitope specificity of p67C sera from immune and susceptible cattle (increase 
composition of peptide chip to proteome) 
4. Survey of BCR repertoire (sample at peak response; purify with p67C?)  
5. Make recombinant antibodies and determine specificity and function 
 
Need to complete contract with Atreca; share reagents; design experiments. 
 
Group 3: Sporozoite antigen discovery 
convened by Lucilla 
 
Scope: To define new antigens that induce sporozoite neutralizing antibodies 
 
Actions:  
1. Identify members of the Focus group 
2. Convene meetings – weekly for first 3 months, decide on later intervals 
3. Update of detailed activities 
4. Identification of bottlenecks to get people started 
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5. Time table of detailed activities 
6. What protein on the peptide chip 
7. Which sera to use on the chip 
8. Plan procedure for mice antibody library 
 
Group 4: Reagents – communal resources 
convened by Lotte 
 
Scope: To collate and catalog existing resources, new resources as generated, a list of resources 
required. 
 
Actions: 
1. Discussion within Consortium to define new needs. 
2. Collate lab protocols 
3. Reagents database 
a. mAbs, hybridomas 
b. Tetramers, BoLA 
c. Cell lines (TpM, CD8, CD4) 
d. Stabilates (of ?) 
e. Recombinant proteins 
f. Recombinant cytokines 
4. Shipping information (forms etc?) 
5. Link to BoLA database 
6. Link to genomics database 
7. April 2015 
a. Preliminary database available 
b. Meeting of group to provide feedback before release to Consortium 
8. Representatives from each site: Chairs – Lotte & Lindsay 
a. ILRI – Anna 
b. Edinburgh – Lotte 
c. WSU – Lindsay 
d. Oxford - ? 
e. UoT – Fred 
f. UoC – Soren 
g. IGS – Joana 
h. Antwerp – Ine 
 
Group 5: Schizont antigen discovery 
convened by Tim 
 
Scope 
The scope of the focus group needs to consider that the current work funded in the consortium is 
using both traditional antigen discovery methods (T-cell screening of peptide libraries) and more 
novel methods (MHCI elution and algorithm based). It is important that for maximum output 
potential there is adequate communication and coordination of the activities between the groups 
primarily performing ‘traditional’ methods (ILRI, WSU and ROSLIN) and those primarily involved in 
the ‘novel methods’ (Oxford, Buenos Aires, Copenhagen and Maryland). In addition to a strong effort 
at coordination the scope should include  
 Selection of antigens for traditional screening 
 MHC haplotypes to focus on  
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 Methodologies to use for screening and how to best sharing techniques and if necessary 
harmonise 
 Reagents required for screening (MHC transfected cell lines, mAb for read out systems, ipp 
etc. , peptide resources…..) 
Agenda 
There was a strong feeling that it was necessary for several of the issues raised during the discussion 
to be dealt with urgently. Most pressing were: 
1 – MHC haplotypes on which the ‘novel’ techniques should focus. Due to a desire to i) rapidly 
generate MHC tetramers that could then be deployed in ongoing experiments and ii) use the pMHCI 
data to support the NetpanMHC algorithm for the MHC haplotypes we are focused on, that work at 
Copenhagen and Oxford will stall unless the MHC haplotypes/alleles to focus on aren’t defined 
imminently. 
2 – Transfer of techniques used for screening – to ensure harmonisation of work and avoid 
unnecessary difficulties in establishing techniques that may already be working in other labs (e.g. 
interest from Nicholas for details of the LDH assay being used at ROSLIN and Wendy about different 
IFNG read-out systems available). 
IT WAS THEREFORE DECIDED TO INITIATE THE FIRST SKYPE MEETING IN THE FIRST WEEK OF MARCH. 
HOW TO PROCEED FROM THERE WILL DEPEND ON PROGRESS AND NECESSITY. 
 
Group 6: T. parva genome resources 
convened by Joana 
 
Scope: Provide reference and comparative genome sequence data to support current and future 
activities in ECF. 
 
Actions: 
1. Identify parasite isolates for WGS in order to generate polymorphism estimates (improve 
ITM?) 
a. Joana to generate spreadsheet to log isolates and metadata 
b. Over next 2~3 weeks, relevant parties find what they have and fill out spreadsheet 
c. In one month – conference call for final selection to sequence 
2. Identify life-cycle stages for RNAseq 
a. Sporozoites/sporoblasts of Muguga and Chitongo 
3. Establish best route to get material to IGS 
a. Probably through ILRI as there is existing permission for this 
 
Group 7: Antigen delivery systems 
convened by Don 
 
Scope: To define the best methods to induce protective anti-sporozoite and anti-schizont immune 
responses 
 
Actions: 
1. List of systems 
2. Adjuvants 
3. Measurement and standards 
4. Distribution of vectors 
5. Share stocks – QA on stocks 
6. Share data 
7. Recommendation on use 
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Group 8: Proof-of concept 
Convened by Ivan 
 
Scope: To define and standardize the parameters to differentiate immune for susceptible cattle to 
sporozoite needle challenge (?) 
 
Actions: 
1. Generic 
a. Define sporozoite challenge – stock and dose 
b. ECF index to measure disease severity 
c. Define protection/non-protection 
2. Schizont 
a. Choice of antigens/BoLA haplotypes for testing delivery systems 
b. Standardize protocols for immunological monitoring 
c. Other samples to archive 
3. Sporozoite 
a. ??? 
 
Action: Calendar of meetings 
1. Whole consortium once a year face to face. Next meeting week of 1-3 February 2016 
 
2. PMC meeting 4 times a year, once face to face, 3 time virtual 
 
3. Monthly science meet-ups, virtual, led by focus groups or others, rotational 
 
4. Several small focus group face to face convenings, as needed, on different topics 
 
5. EAC meeting twice a year, once virtual, once face to face, invited to join any others as 
needed/interested 
 
Action: Communications 
 
The focus groups and the more regular meetings are intended to improve internal communications 
across the consortium 
 
In addition, work is needed on: 
 
• The Yammer network – as a means to regular sharing and updating on consortium activities 
 
• The ILVAC website – as a vehicle to report to the wider world on consortium activities and 
results 
 
• The ‘Genomics’ package website. Action: Joana (branding needs to be checked) 
 
• An email exchange platform (?) to facilitate more practical and hands-on exchanges among 
the ECF ‘tech’ people 
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